A Cost-Benefit Analysis of Neonatal Screening Tests for Maple Syrup Urine Disease, Homocystinuria, Galactosemia, and Congenital Adrenal Hyperplasia.
- Author:
Shin Young PARK
1
;
Dong Il KIM
;
Dong Hwan LEE
Author Information
1. Department of Pediatrics, College of Medicine, Soonchunhyang University, Seoul, Korea. ldh@hosp.sch.ac.kr
- Publication Type:Original Article
- Keywords:
Neonatal screening test;
Cost-benefit;
Efficacy
- MeSH:
Acer;
Adrenal Hyperplasia, Congenital;
Cost-Benefit Analysis;
Galactosemias;
Homocystinuria;
Humans;
Infant, Newborn;
Korea;
Maple Syrup Urine Disease;
Mass Screening;
Metabolism, Inborn Errors;
Neonatal Screening;
Prevalence
- From:Journal of Genetic Medicine
2008;5(2):111-118
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Neonatal screening tests are increasingly being used forearly diagnosis of inborn errors of metabolism (IEM) in the hope of avoiding the severe developmental delay, acute illness, and death that may result from these diseases. In this study, a cost-benefit analysis was performed on the neonatal screening of maple syrup urine disease, homocystinuria, galactosemia, and congenital adrenal hyperplasia in Korea. MATERIALS AND METHODS: This study included 1,259,220 Korean newborns born between January 2005 to December 2007, who were screened for maple syrup urine disease, homocystinuria, galactosemia, and congenital adrenal hyperplasia. We calculated and compared the total costs in cases where these four screening tests were implemented, and those where they were not. RESULTS: There were no benefits to screening for maple syrup urine disease or homocystinuria due to their low prevalence for these two tests, the costs exceeded the benefits at benefit:cost ratios of 0.5:1 and 0.6:1, respectively. In contrast, benefits far exceed costs at a ratio of 4.1:1 for galactosemia and 2.9:1 for congenital adrenal hyperplasia. The average benefit:cost ratio for all four tests was 2.0:1. CONCLUSION: Neonatal screening tests for maple syrup urine disease, homocystinuria, galactosemia, and congenital adrenal hyperplasia are financially viable.
